Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide

(2019) Philippe Moreau et al.   Blood Cancer Journal

Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials

(2019) Adeela Mushtaq et al.   Clinical Lymphoma Myeloma & Leukemia

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

(2019) Paul G Richardson et al.   LANCET ONCOLOGY

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

(2019) Saad Z. Usmani et al.   BLOOD

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

(2019) David S. Siegel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies

(2018) Praful Ravi et al.   Blood Cancer Journal

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

(2018) Laurent Garderet et al.   BLOOD

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

(2017) S K Kumar et al.   LEUKEMIA

Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor

(2017) Brian J. North et al.   PLoS One

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

(2016) M. A. Dimopoulos et al.   BLOOD

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

(2016) R F Cornell et al.   BONE MARROW TRANSPLANTATION

Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma

(2016) Emily Rychak et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of relapsed and refractory multiple myeloma

(2016) Pieter Sonneveld et al.   HAEMATOLOGICA

Treatment of relapsed and refractory multiple myeloma

(2016) Pieter Sonneveld et al.   HAEMATOLOGICA

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide

(2015) Deepika S. Das et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

(2015) Katja Weisel et al.   Clinical Lymphoma Myeloma & Leukemia

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

(2014) P. G. Richardson et al.   BLOOD

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

(2014) E M Ocio et al.   LEUKEMIA

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02

(2013) X. Leleu et al.   BLOOD

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA